Physician profile
Brian Brimmage
NPI 1134567787
$2,258.94
in general payments reported to CMS, 2019-2025
28 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $194 · 2021: $250 · 2022: $447 · 2023: $540 · 2024: $275 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,014 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.66 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $441.58 | 2019-2025 | |
| Astellas Pharma US INC | $233.84 | 2022-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $220.86 | 2020-2023 | Lo Loestrin Fe, Orilissa |
| Pfizer INC. | $180.38 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $174.34 | 2019-2023 | |
| Daiichi Sankyo INC. | $156.97 | 2019-2022 | |
| Exeltis, USA INC. | $101.99 | 2020-2025 | Slynd |
| Sumitomo Pharma America, INC. | $86.39 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $70.25 | 2021-2023 | |
| Evofem Biosciences, INC. | $67.53 | 2021-2025 | Solosec, Phexx, Phexxi |
| Coopersurgical, INC. | $63.05 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Aspira Women'S Health INC | $60.12 | 2021-2024 | Ova1 |
| Therapeuticsmd, INC. | $48.48 | 2019-2020 | |
| Organon LLC | $41.00 | 2023-2024 | Nexplanon |
| Shield Therapeutics INC | $39.51 | 2023-2024 | Accrufer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $35.13 | 2023 | Twirla |
| Hologic Sales and Service, LLC | $35.09 | 2024-2025 | Fetal Fibronectin Enzyme Immunoassay, Novasure, Acessa Provu System |
| Boston Scientific Corporation | $34.19 | 2023 | |
| Biogen, INC. | $28.82 | 2025 | Zurzuvae |
| Mylan Pharmaceuticals INC. | $25.28 | 2019 | |
| Scynexis, INC. | $23.66 | 2022 | |
| Medicem INC. | $18.63 | 2020 | |
| Exact Sciences Corporation | $17.06 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.73 | 2019 | |
| Medtronic, INC. | $15.09 | 2021 | |
| Amgen INC. | $12.49 | 2019 | |
| Covidien Lp | $11.48 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brimmage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.